Medannex is an award-winning clinical-stage Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1.
“MDX-124 could provide a new treatment option as a single agent or in combination with established cancer therapies, and clinical trials are now eagerly anticipated.”
Professor Daniel Palmer,
Department of Molecular &
Clinical Cancer Medicine,
University of Liverpool
Our goal is to improve the lives of people impacted by cancers and autoimmune diseases with our first-in-class therapy targeting annexin-A1.
Supported by both Scottish Enterprise and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.
We recently completed pivotal toxicology studies and cGMP manufacturing of our lead candidate ‘MDX-124′ in preparation for clinical trials in 2022. MDX-124 is the first monoclonal antibody to target annexin-A1, a protein in the immune system that plays a key role in inflammation and the development of numerous cancers, autoimmune conditions and other diseases.
Medannex won both ‘Investment of the Year’ and ‘Outstanding Skills Development’ at Scotland’s Life Sciences Annual Awards 2021 and our Chairman, Professor Christopher Wood, was presented with the ‘Lifetime Achievement Award’.
We look forward to generating our first clinical oncology data with MDX-124 in 2022.
We are currently engaging with investors regarding a Series C financing. For more information please contact info@medannex.org
